Liquidia (NASDAQ:LQDA) Cut to Hold at Wall Street Zen

Liquidia (NASDAQ:LQDA) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

A number of other research firms have also recently commented on LQDA. Raymond James Financial reissued a “strong-buy” rating and set a $47.00 target price on shares of Liquidia in a research report on Tuesday, November 4th. HC Wainwright lifted their price target on shares of Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. BTIG Research reissued a “buy” rating and issued a $49.00 price objective on shares of Liquidia in a research report on Tuesday, November 4th. Wells Fargo & Company initiated coverage on Liquidia in a research report on Monday, October 20th. They set an “overweight” rating and a $31.00 target price on the stock. Finally, Needham & Company LLC increased their price target on Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $38.56.

Liquidia Trading Up 1.4%

Shares of LQDA opened at $34.41 on Friday. Liquidia has a 12 month low of $10.37 and a 12 month high of $34.75. The stock’s 50-day moving average is $26.29 and its two-hundred day moving average is $21.85. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96. The stock has a market cap of $2.99 billion, a PE ratio of -23.90 and a beta of 0.48.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.41. The business had revenue of $54.34 million for the quarter, compared to the consensus estimate of $18.86 million. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The firm’s revenue was up 1106.7% on a year-over-year basis. Equities analysts forecast that Liquidia will post -1.51 earnings per share for the current fiscal year.

Insider Transactions at Liquidia

In other Liquidia news, CFO Michael Kaseta sold 1,166 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $32.19, for a total transaction of $37,533.54. Following the sale, the chief financial officer owned 353,823 shares in the company, valued at $11,389,562.37. This represents a 0.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Rajeev Saggar sold 71,381 shares of Liquidia stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $27.00, for a total value of $1,927,287.00. Following the completion of the transaction, the insider owned 176,549 shares of the company’s stock, valued at approximately $4,766,823. The trade was a 28.79% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 215,168 shares of company stock valued at $5,675,425 over the last 90 days. Corporate insiders own 26.50% of the company’s stock.

Institutional Trading of Liquidia

A number of institutional investors and hedge funds have recently modified their holdings of LQDA. NewEdge Advisors LLC acquired a new position in shares of Liquidia in the 2nd quarter valued at about $25,000. Skandinaviska Enskilda Banken AB publ bought a new position in Liquidia in the third quarter worth about $30,000. Steward Partners Investment Advisory LLC boosted its stake in Liquidia by 24.0% in the second quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock valued at $77,000 after acquiring an additional 1,200 shares during the period. Quarry LP acquired a new position in Liquidia in the first quarter valued at approximately $79,000. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Liquidia by 281.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock valued at $83,000 after purchasing an additional 4,927 shares during the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).